5G·

Lawmakers Urge FDA Crackdown on Fake GLP-1 Drugs

$HIMS (+3,55%)
$NOVO B (-2,99%) | via overnightstocks.com

• U.S. lawmakers are pressing the FDA to take stronger action against counterfeit versions of GLP-1 drugs like Ozempic and Wegovy.

• Rising demand for weight-loss treatments has led to a surge in unregulated, fake products sold online and through compounding pharmacies.

• This development increases regulatory pressure, particularly impacting legitimate suppliers like $NVO (Novo Nordisk) and telehealth platforms like $HIMS offering GLP-1 treatments.

• Lawmakers stress the public health risk and urge immediate enforcement to ensure patient safety and drug integrity.

6 Commenti

Shell@Shell

This is why I sold my $HIMS stocks recently. They depend completely on compounded drugs which is a grey area which may be enforced by FDA at some point

•

Spadan22@Spadan22

@Shell you have obviously absolutely no idea what hims does😂

••

Shell@Shell

@Spadan22 i do actually, but maybe you don’t. I followed hims house quite some time for example.

••

Spadan22@Spadan22

@Shell okay then tell me more. What they are doing is completely legal.

••

Shell@Shell

I guess you should do more research on the risks of the stocks you invest in heavily if you ask this question. Yes, possible upside is huge for hims, but rule number one: ‘never lose money’. Potential downside of loss on the stock at this valuation is high if the business model of relying solely on compounded drugs is disrupted. Ask chat gpt: ‘Why is hims operating in a grey area with compounding drugs and is it possible the business model gets disrupted’. You’ll learn more

•

0LIV3R@PIXELINVESTOR

So in Short words good for Novo and not good for HIMS? 🤔

•